HomeCompareAUTR vs ABBV

AUTR vs ABBV: Dividend Comparison 2026

AUTR yields 335.57% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AUTR wins by $3260.44M in total portfolio value
10 years
AUTR
AUTR
● Live price
335.57%
Share price
$0.60
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3260.54M
Annual income
$2,055,553,271.84
Full AUTR calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AUTR vs ABBV

📍 AUTR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAUTRABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AUTR + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AUTR pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AUTR
Annual income on $10K today (after 15% tax)
$28,523.49/yr
After 10yr DRIP, annual income (after tax)
$1,747,220,281.06/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, AUTR beats the other by $1,747,199,225.06/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AUTR + ABBV for your $10,000?

AUTR: 50%ABBV: 50%
100% ABBV50/50100% AUTR
Portfolio after 10yr
$1630.32M
Annual income
$1,027,789,021.80/yr
Blended yield
63.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AUTR
No analyst data
Altman Z
0.8
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AUTR buys
0
ABBV buys
0
No recent congressional trades found for AUTR or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAUTRABBV
Forward yield335.57%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$3260.54M$102.3K
Annual income after 10y$2,055,553,271.84$24,771.77
Total dividends collected$3143.89M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AUTR vs ABBV ($10,000, DRIP)

YearAUTR PortfolioAUTR Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$44,257$33,557.05$11,550$430.00+$32.7KAUTR
2$186,153$138,797.74$13,472$627.96+$172.7KAUTR
3$744,798$545,614.25$15,906$926.08+$728.9KAUTR
4$2,837,124$2,040,190.61$19,071$1,382.55+$2.82MAUTR
5$10,298,906$7,263,182.70$23,302$2,095.81+$10.28MAUTR
6$35,660,692$24,640,863.53$29,150$3,237.93+$35.63MAUTR
7$117,895,951$79,739,010.53$37,536$5,121.41+$117.86MAUTR
8$372,523,411$246,374,742.82$50,079$8,338.38+$372.47MAUTR
9$1,126,157,153$727,557,103.40$69,753$14,065.80+$1126.09MAUTR
10$3,260,541,426$2,055,553,271.84$102,337$24,771.77+$3260.44MAUTR

AUTR vs ABBV: Complete Analysis 2026

AUTRStock

Autris, through its subsidiary, NitroHeat, LLC, assembles and supplies nitrogen generators, air filtration systems, compressed air heaters, and heated hoses. Its products include NitroMax30, a nitrogen generator producing 30cfm of pure nitrogen; HeatPro200, a compressed air heater for heating compressed air or nitrogen up to a maximum of 200f; MaxDry200, a tri stage filter, membrane dryer, and heater that is used to supply clean dry air for painting and other compressed air applications, including powder coating; and heated hoses, a sub component of the HeatPro200 and MaxDry200. The company supplies its products to automotive and industrial paint service providers, and industrial component manufacturers, as well as auto collision facilities through a distributor network in the United States, Canada, Holland, Germany, and China. Autris is based in Los Angeles, California.

Full AUTR Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AUTR vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AUTR vs SCHDAUTR vs JEPIAUTR vs OAUTR vs KOAUTR vs MAINAUTR vs JNJAUTR vs MRKAUTR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.